OptiNose, Inc. Common Stock
OPTN
OPTN: OptiNose Inc is a specialty pharmaceutical company that focuses on the development and commercialization of products for patients treated by ear, nose, and throat, and allergy specialists. Its product includes XHANCE (fluticasone propionate) nasal spray, 93 micrograms (mcg), a therapeutic utilizing its proprietary Exhalation Delivery System (EDS) that delivers a topically-acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps. The XHANCE is able to deliver medication to the primary site of inflammation high and deep in the nasal passages in regions not adequately reached by intranasal steroids.
moreShow OPTN Financials
Recent trades of OPTN by members of U.S. Congress
Recently reported changes by institutional investors
Quarterly net insider trading by OPTN's directors and management
Government lobbying spending instances
-
$10,000 Jul 20, 2021 Issue: Health Issues Budget/Appropriations
-
$30,000 Apr 19, 2021 Issue: Health Issues Budget/Appropriations
-
$20,000 Jan 19, 2021 Issue: Health Issues
New patents grants
-
Patent Title: Intranasal administration Aug. 22, 2023
-
Patent Title: Intranasal administration Jul. 25, 2023
-
Patent Title: Delivery of gases to the nasal airway Jul. 04, 2023
-
Patent Title: Nasal delivery devices Mar. 14, 2023
-
Patent Title: Powder delivery devices Feb. 07, 2023
-
Patent Title: Nasal administration Jan. 17, 2023
Federal grants, loans, and purchases
Followers on OPTN's company Twitter account
Number of mentions of OPTN in WallStreetBets Daily Discussion
Recent insights relating to OPTN
Recent picks made for OPTN stock on CNBC
ETFs with the largest estimated holdings in OPTN
Flights by private jets registered to OPTN